Restricted accessResearch articleFirst published online 2022-12
Use of gonadotropin-releasing hormone agonists for ovarian preservation in patients receiving cyclophosphamide for systemic lupus erythematosus: A meta-analysis
Cyclophosphamide (CYC) has known cytotoxic effects on ovarian reserve and has been linked to premature ovarian failure (POF) in systemic lupus erythematosus (SLE). The concurrent use of gonadotropin-releasing hormone agonists (GnRHas) is postulated to preserve ovarian function by reducing the number of follicles exposed to CYC, but there is paucity of data to establish its efficacy. We conducted a meta-analysis to summarize the effect of concurrent GnRHa use in persevering ovarian function and pregnancy.
Methods
English language databases of PubMed, Embase, and Cochrane were searched to include studies published between 2000 and 2021. Studies in females with rheumatic diseases receiving concurrent GnRHa and CYC therapy to evaluate ovarian preservation as defined by amenorrhea, follicle stimulating hormone (FSH), anti-mullerian hormone (AMH), or estradiol levels or successful pregnancy were included. We used a fixed effect, exact, Mantel-Haenszel approach to estimate the overall odds ratio (OR) and associated 95% confidence intervals (95% CIs).
Results
Seven studies with 218 female patients were included. The ovarian function was preserved in 125/132 (94.6%) of women who received GnRHa concurrently with CYC compared to 50/86 (58%) of women who did not receive GnRHa (OR = 10.3, CI = 4.83–36.29). The OR for pregnancy with GnRHa use = 2.94 (CI = 1.04–9.89).
Conclusion
Our results based on limited published studies suggest that concurrent GnRHa use preserves ovarian function and increase odds of pregnancy. It can be considered for premenopausal SLE females receiving CYC. Long-term follow-up studies are needed to establish the efficacy and safety of GnRHa use for ovarian preservation.
AngumFKhanTKalerJ, et al.The prevalence of autoimmune disorders in women: a narrative review. Cureus2020; 12(5): e8094.
2.
ZusmanEZSayreECAvina-ZubietaJA, et al.Patterns of medication use before, during and aftter pregnancy in women with systemic lupus erythematosus: a population-based cohort study. Lupus2019; 28: 1205–1213.
3.
TsokosGC. Systemic lupus erythematosus. N Engl J Med2011; 365(22): 2110–2121.
4.
BlumenfeldZMOSchultzNBoulmanN, et al.Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases. Semin Arthritis Rheum2011; 41(3): 346–352.
5.
HarwardLEMitchellKPieperC, et al.The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus2013; 22(1): 81–86.
6.
SomersECMarderWChristmanGM, et al.Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum2005; 52(2761–7): 81–86.
7.
AkawatcharanguraPTaechakraichanaNOsiriM. Prevalence of premature ovarian failure in systemic lupus erythematosus patients treated with immunosuppressive agents in Thailand. Lupus2016; 25(4): 436–444.
8.
BermasBLLisaRSammaritano. Fertility and pregnancy in systemic lupus erythematosus. Systemic Lupus Erythematosus2021.
9.
MouyisMFlintJDGilesIP. Safety of anti-rheumatic drugs in men trying to conceive: a systematic review and analysis of published evidence. Semin Arthritis Rheum2019; 48(5): 911–920.
10.
MokCCChanPTToCH. Anti-mullerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum2013; 65(1): 206–210.
11.
LuongSNIsaacsALiuZ, et al.A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone agonists (GnRHa) in women of child-bearing age with autoimmune rheumatic disease. Expert Rev Clin Immunol2020; 16(3): 321–333.
12.
AmouraZDPSbaiACostedoatN, et al.Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol2002; 29(12): 2571–2576.
13.
McDermottEMPowellRJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis1996; 55(4): 224–229.
14.
MayorgaJAlpizar-RodriguezDPrieto-PadillaJ, et al.Prevalence of premature ovarian failure in patients with systemic lupus erythematosus. Lupus2016; 25(7): 675–683.
15.
CeccarelliFOreficeVPerroneG, et al.Premature ovarian failure in patients affected by systemic lupus erythematosus: a cross-sectional study. Clin Exp Rheumatol2020; 38(3): 450–454.
16.
ClowseMMagderLPetriM. Cyclophosphamide for lupus during pregnancy. Lupus2005; 14(8): 593–597.
17.
BellverJPellicerA. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrom. Fertil Steril2009; 92(6): 1803–1810.
18.
ChakravartyEFSammaritanoLR. Pregnancy and autoimmune disease, reproductive and hormonal issues. Dubois' Lupus Erythematosus Relat Syndromes2019.
19.
GuballaNSammaritanoLSchwartzmanS, et al.Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum2000; 43(3): 550–556.
20.
OreficeVCeccarelliFPerroneG, et al.Treatment with gonadotropin releasing hormone agonists in systemic lupus erythematosus patients receiving cyclophosphamide: a long-term follow-up study. Isr Med Assoc J2020; 22(6): 343–347.
21.
MangerKWildtLKaldenJR, et al.Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev2006; 5(4): 269–272.
22.
Ben-AharonIGafter-GviliALeiboviciL, et al.Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat2010; 122(3): 803–811.
23.
SammaritanoLRBermasBLChakravartyEE, et al.American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res2020; 72(4): 461–488.
24.
OktayKHarveyBEPartridgeAH, et al.Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol2018; 36(19): 1994–2001.
25.
PageMJMoherDBossuytPM, et al.PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ2021: 372.
26.
BlumenfeldZShapiroDShteinbergM, et al.Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus2000; 9(6): 401–405.
27.
LiangLQQiuQYangXY, et al.[Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide]. Zhonghua Yi Xue Za Zhi2008; 88(15): 1009–1011.
28.
PacucciVACeccarelliFPerroneG, et al.SAT0260 ovarian function preservation with gonadotropin-releasing hormone analogues in patients with systemic lupus erythematosus treated with cyclophosphamide. Ann Rheum Dis2017; 76: 872.
29.
OrtmannOWeissJMDiedrichK. Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online2002; 5(Suppl 1): 1–7.
30.
BlumenfeldZ. Fertility preservation using GnRH agonists: rationale, possible mechanisms, and explanation of controversy. Clin Med Insights Reprod Health2019; 13: 1179558119870163.
31.
RiisBJCCJohansenJSJacobsonJ, et al.Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?J Clin Endocrinol Metab1990; 70: 920–924.
32.
MattaWHShawRWHespR, et al.Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol1988; 29(1): 45–51.
33.
PaolettiAMSerraGGCagnacciA, et al.Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril1996; 65(4): 707–710.
34.
DawoodMYRamosJKhan-DawoodFS. Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertil Steril1995; 63(6): 1177–1183.
35.
AlarfajASKhalilN. Fertility, ovarian failure, and pregnancy outcome in SLE patients treated with intravenous cyclophosphamide in Saudi Arabia. Clin Rheumatol2014; 33(12): 1731–1736.
36.
InHoutJIJBormJFGoemanJJ, et al.Small studies are more heterogeneous than large ones: a meta-meta-analysis. J Clin Epidemiol2015; 68: 860–869.
37.
GuoloAVarinC. Random-effects meta-analysis: the number of studies matters. Stat Methods Med Res2017; 26(3): 1500–1518.
38.
LairdDRLairdN. Meta-analysis in clinical trials. Controlled Clin Trials1986; 7: 177.
39.
EfthimiouO. Practical guide to the meta-analysis of rare events. Evid Based Ment Health2018; 21(2): 72–76.
